The Use of Biomarkers-A Chemo Sensitivity Report For Cholangiocarcinom
- This topic has 39 replies, 8 voices, and was last updated 10 years, 7 months ago by
.
-
Posts
-
Hi,eli,
it works, all I need is click the download button,and then I can adjust the size of the copy.
Thanks,it will help all of us in the future.
BTW yes, this is a general info copy ,I will share the rest later.
God bless.Percy, I see one report page. Is that all you wanted to share? Or are there any other pages?
Since the page doesn’t have any personal details, I took the liberty to put it on a free image sharing service: imgur.com
Here’s the link:
http://i.imgur.com/QtdsG.jpgWhile the image is hosted on imgur, it’s also possible to embed it right here:
Hi, eli,
Let see how it looks,I hope it works.
Thanks
God blesshttps://docs.google.com/open?id=0B9UTQLyQ5e2PNDg3YTg1NWQtYTRmMi00OTFiLWE4ZmYtMGE5NjYwZjBlMDA3
You don’t have to convert the report to PDF.
1. Open the image in Windows Paint
2. Wipe out all personal details such as name, address, etc. Draw solid black rectangles over them.
3. Save the new image
4. Put it on a free file hosting service ***
5. Post the link to the shared file here*** If you have gmail account, you can use Google Documents as your file hosting service:
1. Log into your gmail account
2. Switch to Documents (a link at the top of the page)
3. Upload your report file from your hard drive
4. Share the file
5. Post the link to the shared file hereHi,Eli,
Your understanding is correct about the “Target Report Now”.
And that is what it is as you said they listed the drug that are EXPECTED to work.and that report cost about 8,000 insurance money.
I did it because I want to know exactly what a patient can be expected from the report just in case patient on the web ask me questions about it;and partly also because the vision ofASCO they put out recently.
Unless the patient is very rich and can pay the lab to do the fresh tissue report,I personally think it will be done very often.
BTW,my report is on image format and need to convert to PDF format in order it can be share on the web.
God bless.Did they actually test various chemo protocols on your live cell cultures? If not, your test is not the same as the chemo sensitivity test that I described in my previous post.
My understanding is:
[list=*]
[*]”Target Now” is a biomarkers test. It measures a number of known biomarkers in the tumor. Once biomarkers are measured, they list the drugs that are expected to work best. They don’t actually test those drugs on live cells. This test does not require a fresh biopsy.[/*]
[*]Chemosensitivity test requires live cells that can be grown in test tubes. Your oncologist tells the lab which drug combinations to test. The lab tests the requested drug combinations on live cell cultures and reports how well they work. This test requires a fresh biopsy.[/*]
[/list]Hi,Eli,
The top message that I posted is the first page of my chemo sensitivity report .I cannot convert the image file to the PDF format for the copied report .that is why I type it out.Any suggestions so I can share the rest of the report on this web site.
Thanks again.
The chemo sensitivity report is called “Target Now” report by the company.
Depends on where you order the report, you may not need fresh tissue sample for the new machine that some lab use to test your sample.
God bless.Hi Percy,
What do you think about Chemo Sensitivity and Resistance Assays testing? Cell Culture Drug Resistance Testing is another name for the same test.
Did you know about this test before your second surgery?
If yes, why did you choose biomarkers test rather than chemosensitivity test?
A short summary of how it works:
Quote:When a patient has an infection, doctors often send a sample of infected blood or tissue to a lab where they can grow the bacteria and see which antibiotics are most effective (called Bacterial Culture and Sensitivity Testing). Chemosensitivity testing is an attempt to do something similar for cancer; fresh samples of the patient’s tumor from surgery or a biopsy are grown in test tubes and tested with various drugs. Drugs that are most effective in killing the cultured cells are recommended for treatment. It is highly desirable to know what drugs are effective against your particular cancer cells before highly-toxic agents are systemically administered to your body.More details here:
http://csn.cancer.org/node/145884The test requires a fresh biopsy sample. It’s not an option for many CCA patients, because CCA is hard to biopsy. My guess is it could be an option for two kinds of CCA patients:
– CCA patients with intrahepatic tumor that can be biopsied
– CCA patients who can pre-arrange the test before the surgery, and do it right after the surgeryHi, everyone,
Here is another company that can provide biomarkers lab tests.;and it may be more advance according to this article segment than the “Target Now “report.(please see below)Roche’s cobas EGFR Mutation Test received a CE mark. The regulatory stamp means the test will be commercially available as a companion diagnostic to identify non-small-cell lung cancer (NSCLC) patients with EGFR mutations who may benefit from anti-EGFR tyrosine kinase inhibitors.
Roche itself has a tyrosine kinase inhibitor for NSCLC, Tarceva. The drug was approved by the EC in September as first-line monotherapy in patients with locally advanced or metastatic NSCLC with EGFR-activating mutations.
Carried out on a section of tumor, the real-time PCR-based cobas EGFR Mutation Test detects 41 mutations across exons 18, 19, 20, and 21 of the EGFR gene. The firm claims the assay has a higher degree of sensitivity than Sanger sequencing and delivers test results within eight hours.
The cobas EGFR Muation Test is the third cobas oncology diagnostic to be granted a CE mark this year. It joins the cobas BRAF Mutation Test for metastatic melanoma and the cobas KRAS Mutation Test for advanced colorectal cancer. All assays are carried out on the cobas 4800 system v2.0.
God bless.
eli…that is interesting to hear. The CA 19-9 is elevated in about 65 % of hepatobiliary cancer. It is taken at onset of chemotherapy treatments in order to monitor response and may be ordered several times throughout treatment. Often times it will be monitored post treatment and taken in consideration in addition to Ct or MRI’ scans.
All my best wishes,
MarionRe CA19-9: I noticed that US patients discuss it a lot. I asked our oncologist if he is going to use it. He said no. Too many false negatives/positives. He actually said that government insurance might not cover the cost of the test for surveillance purposes.
PCL, thank you for your response. Very thorough, as usual.
I asked just to figure out how much effort I should put into researching this subject. If the tissue is not viable, I don’t have to study the use of biomarkers.
Sounds like the test might be viable. I will ask our oncologist what he thinks.
Hi,Eli,
You can request the pathology dept. of the hospital your wife had the surgery for the Tissue block and slides. However, it is not the 5month I will worry about but whether the hospital will have ENOUGH of the tissue left for you to do the bio markers chemo sensitivity.But it won’t hurt to find out.
BTW,the tissue is preserved in paraffin and is good for years.
One thing is that ,I don’t know whether it will be worth it if you have to pay for it 100% by yourself and not by your government. If I were you,I will wait till the next scan to see if the current chemo is working or not. If it works,then You may not need to spend the thousands of dollars.Mine was paid by the insurrance.
The bio markers test are not 100% as useful as it seems to be partly because it is expensive and is not widely used by the physicians because of the limitations of the results .(ie: like the CA19-9 is a bio marker for CCA,but the sensitivity and specificity of the test is still debatable; mine CA19-9 never higher than 28.but as you know it is not correlated with the suggested normal range of<37. And it is different from extra hepatic CCA which you can expect a much higher value.)
God bless.
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.